Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,210.45 +18.71 (+1.57%)
Streaming Delayed Price Updated: 2:59 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
News headline image
Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds ↗
NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial intelligence across research, clinical trials, and supply chains over the next five... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? ↗
Both companies now aim to win in the oral weight loss drug market. 
Via The Motley Fool
News headline image
Cooling Inflation Ignites Market Optimism: December CPI Report Paves Way for Fed Pivot
The Bureau of Labor Statistics released the December 2025 Consumer Price Index (CPI) report on the morning of January 13, 2026, revealing a headline inflation rate of 2.7%. While the headline figure... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
Eli Lilly & Co (NYSE:LLY) Combines High Growth Momentum with a Strong Technical Setup ↗
Via Chartmill
Nvidia, Lilly Team Up For $1B Drug AI Lab ↗
Via Stocktwits
Topics Artificial Intelligence
ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest ↗
Via Stocktwits
News headline image
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? ↗
The gap may be too hard to close in the next 12 months. 
Via The Motley Fool
News headline image
What to Expect From Eli Lilly’s Q4 2025 Earnings Report
Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits. 
Via Barchart.com
News headline image
Is the Vanguard Dividend Appreciation ETF a Buy Now? ↗
This Vanguard ETF could be appealing to investors seeking both growth and income. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Why Tempus AI Stock Rose Today ↗
The data provider's artificial intelligence-driven solutions are accelerating drug discovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security
On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
This NVIDIA Partnership Shows How Big AI Can Really Get ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Nvidia Stock Continues To Crawl But Analysts See Strong Upside Ahead ↗
Nvidia said on Monday that it will partner with Eli Lilly to fund a new artificial intelligence research lab, committing up to $1 billion over five years. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Nvidia Partners With Biotech Firms On AI Drug Discovery ↗
Nvidia announced AI partnerships with biotech firms to transform the way lifesaving drugs are discovered and manufactured. Nvidia stock rose. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio ↗
BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment. 
Via Investor's Business Daily
News headline image
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The "Low-Hire, Low-Fire" Safety Net: Labor Resilience Provides Bullish Floor for Wall Street in 2026
As the dust settles on the first trading weeks of 2026, the U.S. economy finds itself in a precarious yet surprisingly durable equilibrium. Despite a political landscape fraught with the friction of an... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26
In a move that signals the definitive arrival of the "AI-first" era for the pharmaceutical industry, Eli Lilly and Company (NYSE:LLY) and NVIDIA Corporation (NASDAQ:NVDA) announced a massive expansion... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗
Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined. 
Via Stocktwits
News headline image
An Investor's Guide to 2026 ↗
What does the new year bring to investors? 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Stocks to Love in 2026 ↗
Are you looking for investment opportunities in 2026? 
Via The Motley Fool
Topics ETFs Initial Public Offering
News headline image
Can This Stock Double Again in 2026? ↗
It's a tough act to follow. 
Via The Motley Fool
News headline image
Is the Schwab U.S. Dividend Equity ETF a Buy Now? ↗
It's time to start thinking strategically -- and even philosophically -- about how seemingly similar funds are actually quite different. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗
It has strong momentum thanks to its current portfolio and several catalysts on the horizon. 
Via The Motley Fool
News headline image
Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?
Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels. 
Via Barchart.com
News headline image
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive... 
Via MarketMinute
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by... 
Via MarketMinute
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.